scispace - formally typeset
Journal ArticleDOI

The different roles of ER subtypes in cancer biology and therapy

TLDR
The changes in the bioavailability of ERs in tumours promote the selective restoration of their activity as one of the major therapeutic approaches for hormone-dependent cancers.
Abstract
By eliciting distinct transcriptional responses, the oestrogen receptors (ERs) ERα and ERβ exert opposite effects on cellular processes that include proliferation, apoptosis and migration and that differentially influence the development and the progression of cancer. Perturbation of ER subtype-specific expression has been detected in various types of cancer, and the differences in the expression of ERs are correlated with the clinical outcome. The changes in the bioavailability of ERs in tumours, together with their specific biological functions, promote the selective restoration of their activity as one of the major therapeutic approaches for hormone-dependent cancers.

read more

Citations
More filters
Journal ArticleDOI

Signal Transduction in Cancer

TL;DR: An examination of the PI3K-Akt and Ras-ERK pathways illustrates how such alterations dysregulate signaling in cancer and produce many of the characteristic features of tumor cells.
Journal ArticleDOI

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

Weiva Sieh, +70 more
- 01 Aug 2013 - 
TL;DR: Clinical trials, stratified by subtype and biomarker status, are needed to establish whether hormone-receptor status predicts response to endocrine treatment, and whether it could guide personalised treatment for ovarian cancer.
Journal ArticleDOI

The potential health effects of dietary phytoestrogens

TL;DR: The literature overview presented in this paper illustrates that several potential health benefits of phytoestrogens have been reported but that, given the data on potential adverse health effects, the current evidence on these beneficial health effects is not so obvious that they clearly outweigh the possible health risks.
Journal ArticleDOI

The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases.

TL;DR: Since estrogen has varied effects in female-predominant autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus, it is mechanistically postulate the potential differential role of estrogen in these chronic debilitating diseases.
Journal ArticleDOI

Addressing the role of obesity in endometrial cancer risk, prevention, and treatment

TL;DR: The molecular mechanisms by which obesity and adipose tissue contribute to the pathogenesis of endometrial cancer are identified and the development of rational behavioral and pharmaceutical interventions aimed at reducing endometrian cancer risk, improving cancer outcomes, and preserving fertility in an increasingly younger population of patients with endometrium cancer are examined.
References
More filters
Journal ArticleDOI

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal ArticleDOI

Cloning of a novel receptor expressed in rat prostate and ovary.

TL;DR: It is concluded that clone 29 cDNA encodes a novel rat ER, which is suggested be named rat ERbeta to distinguish it from the previously cloned ER (ERalpha) from rat uterus.
Journal Article

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Anthony Howell
- 16 May 1998 - 
TL;DR: There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented in this paper, which approximately doubles the amount of evidence from trials of about 5 years of tamoxifier and, taking all trials together, on events occurring more than 5 years after randomisation.
Related Papers (5)